Leerink Partnrs Decreases Earnings Estimates for Belite Bio

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Free Report) - Leerink Partnrs cut their Q2 2025 EPS estimates for Belite Bio in a research note issued to investors on Monday, July 7th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($0.46) per share for the quarter, down from their previous forecast of ($0.35). The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share. Leerink Partnrs also issued estimates for Belite Bio's Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.85) EPS, FY2026 earnings at ($0.50) EPS, FY2027 earnings at $1.25 EPS and FY2028 earnings at $7.05 EPS.

Other analysts have also issued research reports about the stock. Benchmark reiterated a "buy" rating and set a $80.00 target price on shares of Belite Bio in a research note on Wednesday, March 26th. Wall Street Zen lowered shares of Belite Bio from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Belite Bio in a research note on Thursday, May 15th. Finally, HC Wainwright restated a "buy" rating and set a $100.00 price target on shares of Belite Bio in a research report on Thursday, July 3rd. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $96.67.

Belite Bio Stock Up 1.9%

BLTE stock traded up $1.19 during trading on Thursday, hitting $63.22. 180,040 shares of the company's stock traded hands, compared to its average volume of 46,625. Belite Bio has a 52 week low of $43.70 and a 52 week high of $86.53. The stock has a fifty day moving average price of $61.71 and a two-hundred day moving average price of $60.45. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -46.49 and a beta of -1.50.

Hedge Funds Weigh In On Belite Bio

Several institutional investors have recently modified their holdings of the company. GAMMA Investing LLC grew its position in shares of Belite Bio by 9,391.6% during the first quarter. GAMMA Investing LLC now owns 122,441 shares of the company's stock worth $8,108,000 after acquiring an additional 121,151 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Belite Bio during the first quarter worth about $5,538,000. Bank of America Corp DE grew its position in shares of Belite Bio by 36.4% during the fourth quarter. Bank of America Corp DE now owns 18,342 shares of the company's stock worth $1,157,000 after acquiring an additional 4,891 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Belite Bio by 130.3% during the fourth quarter. JPMorgan Chase & Co. now owns 14,636 shares of the company's stock worth $924,000 after acquiring an additional 8,280 shares during the last quarter. Finally, XTX Topco Ltd grew its position in shares of Belite Bio by 30.9% during the fourth quarter. XTX Topco Ltd now owns 7,062 shares of the company's stock worth $446,000 after acquiring an additional 1,668 shares during the last quarter. Institutional investors own 0.53% of the company's stock.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.